BA
Balaxi Pharmaceuticals Ltd (BALAXI)
₹22.80
Mkt cap
₹130 Cr
P/E ratio
53.50
P/B
0.51
Div yield
0.00%
ROE
0.59%
ROCE
3.11%
EPS (TTM)
₹0.43
Book value
₹45
52W range
15–48
Sector
Healthcare
Price history
Previous close
Balaxi Pharmaceuticals Ltd is an IPR-based pharmaceutical Company engaged in producing, stocking, selling, and supplying branded and generic medicines. [1]
NSE BALAXI
Health check
Cautious
ValuationExpensive
ProfitabilityWeak
GrowthHigh
TechnicalsBearish
52-week range
−52.21% from high₹23
₹15+50.00% from low₹48
Current
₹22.80
Prev close
₹22.70
Day
+0.44%
Price performance
1D
+0.44%
1W
−1.04%
1M
−0.13%
3M
−1.38%
6M
+29.18%
1Y
−50.65%
YTD
−15.74%
Financials
Revenue, profit & margin
P/E ratio
53.5×
BALAXI is 55% above the sector median of 34.6×
BALAXI53.5×
Sector median34.6×
| Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Trend | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 65.96 | 54.72 | 60.79 | 59.83 | 65.62 | 77.38 | 73.29 | 76.27 | 70.74 | 56.18 | 72.54 | 70.71 | 80.68 | |
| Expenses | 57.12 | 43.96 | 47.14 | 46.36 | 55.53 | 66.79 | 69.30 | 63.72 | 66.58 | 55.02 | 69.45 | 70.59 | 76.02 | |
| Operating Profit | 8.84 | 10.76 | 13.65 | 13.47 | 10.09 | 10.59 | 3.99 | 12.55 | 4.16 | 1.16 | 3.09 | 0.12 | 4.66 | |
| OPM % | 13.40% | 19.66% | 22.45% | 22.51% | 15.38% | 13.69% | 5.44% | 16.45% | 5.88% | 2.06% | 4.26% | 0.17% | 5.78% | |
| Other Income | -47.68 | 5.93 | 1.51 | -0.70 | -1.85 | -4.11 | 3.94 | -1.69 | -1.78 | 1.59 | 0.10 | 2.92 | -0.99 | |
| Interest | 0.29 | 0.37 | 0.41 | 0.61 | 0.37 | 0.45 | 1.38 | 0.74 | 1.01 | 0.89 | 1.02 | 0.99 | 0.73 | |
| Depreciation | 0.29 | 0.66 | 0.48 | 0.67 | 0.49 | 0.46 | 0.48 | 0.46 | 0.46 | 0.48 | 0.56 | 0.65 | 0.85 | |
| Profit before tax | -39.42 | 15.66 | 14.27 | 11.49 | 7.38 | 5.57 | 6.07 | 9.66 | 0.91 | 1.38 | 1.61 | 1.40 | 2.09 | |
| Tax % | 4.90% | 7.92% | 4.77% | 4.87% | 12.06% | 17.41% | 11.70% | 10.56% | 67.03% | 84.06% | 80.75% | 56.43% | 38.28% | |
| Net Profit | -41.34 | 14.43 | 13.59 | 10.93 | 6.48 | 4.59 | 5.36 | 8.64 | 0.29 | 0.21 | 0.31 | 0.61 | 1.30 | |
| EPS in Rs | -8.07 | 2.82 | 2.65 | 2.01 | 1.17 | 0.83 | 0.97 | 1.57 | 0.05 | 0.04 | 0.06 | 0.11 | 0.24 | |
| Raw PDF |
Earnings
Results dates & reactionsNo upcoming results date on calendar.
Fresh quarters land in the Financials table above, tagged NSE until screener catches up.
Avg earnings-day move +0.58% · closed higher next day 1 of last 1
| Q1FY27 | |
|---|---|
| Broadcast | 5 Aug '26 |
| Earnings day | +0.58% |
| +1 day | +0.71% |
| +5 days | +0.08% |
| +15 days | −6.74% |
| +30 days | −4.12% |
| Filing | XBRL |
Corporate actions
Last 6 monthsNo recent corporate actions
Dividends, splits, and bonuses in the last six months show up here.
Shareholding
as of Jun 202665.99%Promoter
Promoters65.99%
FIIs0.00%
DIIs2.56%
Public31.45%
Ownership trend
Peers
8 companiesValuation vs quality
P/E × ROCE · bubble = market cap| Name | CMP | P/E | Mkt Cap | Div Yld | NP Qtr | Qtr Profit Var | Sales Qtr | Qtr Sales Var | ROCE |
|---|---|---|---|---|---|---|---|---|---|
| Sun Pharma.Inds. | ₹1,837.30 | 34.90 | 4,40,830 | 0.87% | 2,901 | +5.95% | 15,300 | +10.46% | 20.53% |
| Divi's Lab. | ₹9,375.00 | 83.54 | 2,48,877 | 0.32% | 902 | +65.50% | 3,080 | +27.80% | 21.97% |
| Torrent Pharma. | ₹4,840.00 | 82.51 | 1,84,098 | 0.79% | 566 | +5.79% | 4,921 | +54.85% | 15.19% |
| Zydus Lifesci. | ₹1,160.00 | 23.77 | 1,15,710 | 0.09% | 990 | −35.09% | 8,017 | +21.96% | 21.14% |
| Cipla | ₹1,394.50 | 31.48 | 1,12,656 | 0.93% | 786 | −39.19% | 7,119 | +2.33% | 15.49% |
| Laurus Labs | ₹1,954.00 | 96.56 | 1,05,577 | 0.10% | 362 | +125.49% | 2,026 | +29.10% | 17.76% |
| Aurobindo Pharma | ₹1,734.00 | 26.39 | 99,771 | 0.23% | 1,032 | +28.11% | 9,150 | +16.30% | 12.86% |
| Balaxi Pharma | ₹23.55 | 53.50 | 130 | 0.00% | 1 | +348.28% | 81 | +14.05% | 3.11% |
| Median: 158 Co. | ₹433.90 | 34.56 | 2,205 | 0.08% | 13 | +29.57% | 164 | +18.57% | 14.96% |
Filings
Annual reports11
Concall transcripts32
Credit ratings5
Announcements5
Updates 7 Sep - RTA reported nil re-lodgement transfer requests for physical shares in August 2026.General Updates 31 Aug - Balaxi receives WHO-GMP certification for Jadcherla facility; initial product manufacturing has commenced.Change in Director(s) 24 Aug - Shareholders approved re-appointment of Ms. Akshita Ostwal as independent director for five years from September 5, 2026.Shareholders meeting 24 Aug - 83rd AGM held on 24 Aug 2026; shareholders approved audited statements and director reappointments.Shareholders meeting 24 Aug - 83rd AGM held on 24 Aug 2026; all four resolutions passed with requisite majority.